Skip to content

A Pilot fMRI Study of TMS in Late-Life Severe Worry

A Pilot fMRI Study of TMS in Late-Life Severe Worry

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03577106
Acronym
TINA
Enrollment
24
Registered
2018-07-05
Start date
2018-12-06
Completion date
2022-05-04
Last updated
2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders Generalized

Keywords

transcranial magnetic stimulation, TMS, MRI, magnetic resonance imaging, fMRI, functional magnetic resonance imaging, sleep, intermittent theta burst stimulation, iTBS

Brief summary

Investigators will test a novel intervention through experimental therapeutic approach using fMRI-directed Intermittent Theta Burst Stimulation (iTBS), a high frequency TMS paradigm, for the treatment of severe, uncontrollable worry. While worry is a universal human experience, severe and excessive worry has been recently linked to increased risk of stroke and other cardiovascular diseases, increased risk of conversion to Alzheimer's disease as well as to higher risk of all-cause mortality in midlife and late-life. Severe, uncontrollable worry has been repeatedly associated with reduced quality of life and impaired functioning. Current treatment choices (antidepressant/anxiolytic medications and psychotherapeutic interventions) have been proven moderately efficacious in reducing anxiety/depression burden, but ineffective in reducing worry severity, a phenomenon that may contribute to the high relapse rates associated with mood and anxiety disorders. Our research indicated that worry severity is associated with hyperactivation in specific regions such as orbital frontal cortex, superior parietal gyrus, amygdala and parahippocampal gyrus. This pilot study will explore the efficacy of targeting one of these regions with iTBS. Based on investigators' previous results, the most accessible target is the right superior parietal gyrus (rSPG) - a region that remained significantly associated with severe worry after controlling for effects of comorbid depression or overall anxiety. As this region showed an increased in cerebrovascular flow in association with worry severity, investigators will use iTBS (5x/week for 2 weeks) to modulate cortical plasticity in this region and consequently, to reduce worry severity. TMS during wakefulness has been shown to alter subsequent sleep \[4\], Further, changes in sleep in response to TMS has been associated with how participants respond to the TMS as a treatment \[5\]. Thus, the study will measure sleep throughout the protocol to determine whether sleep changes as a function of TMS and whether sleep changes are associated with treatment response.

Detailed description

Background: Twenty percent of older adults in the community report severe worry. While worry is a universal human experience, severe and excessive worry in older adults has been recently linked to increased risk of stroke and other cardiovascular diseases, increased risk of conversion to Alzheimer's disease as well as to higher risk of all-cause mortality. As worry is a transdiagnostic construct, it is present in several mood and anxiety disorders, including major depressive disorder and generalized anxiety disorder. Current treatment choices in late-life (antidepressant/anxiolytic medications and psychotherapeutic interventions) have been proven moderately efficacious in reducing anxiety/depression burden, but ineffective in reducing worry severity, a phenomenon that may contribute to the high relapse rates associated with mood and anxiety disorders in the geriatric population. These elements support the need for novel, experimental interventions specifically designed to target the neural basis of severe worry in late-life. Through a pre-existing study (R01 MH108509), investigators focus on describing the behavior of canonical neural networks during resting state and during worry induction in participants with low-to-high worry. The research indicates that simple induction of worry activates a distinct set of regions (caudate/thalamus, visual cortex, dorsal anterior cingulate). Given the universality and potential evolutionary benefits of worry, investigators believe that the neural network associated with worry induction supports a normal, physiologic experience. However, the regions involved in maintaining worry (hippocampus, thalamus) as well as those associated with severe worry (orbitofrontal cortex, superior parietal gyrus, amygdala, parahippocampal gyrus) support a pathological phenomenon and may represent ideal targets for interventions. This pilot study will test the engagement of therapeutic targets during TBS. Based on the investigators' preliminary results, the most accessible and relevant target is the parietal cortex - a region that in the investigators K 23 sample remained significantly associated with severe worry after controlling for effects of comorbid depression or overall anxiety. As parietal cortex cerebrovascular flow increased in association with worry severity, the investigators will use inhibitory TBS \[high frequency TMS at 1 Hz\] to modulate cortical plasticity and consequently reduce worry severity. To test target engagement, the research team will use the in-scanner worry induction paradigm designed by Dr. Andreescu and her mentors during her K23 award and currently use to probe worry induction in the R01 MH108509. Given the exploratory nature of this proposal and based on our preliminary data, we will use two measures of target engagement: 1) the relative decrease in BOLD signal in the parietal cortex and 2) the relative decrease in rSPG-dACC functional connectivity. Significance: 1. Severe worry in late-life carries a significant health care risk. Worry is defined as a complex affective and cognitive process, negative-affect laden, and relatively uncontrollable \[6\]. While worry is a universal human experience that may confer an evolutionary advantage by modifying threat-related decision-making, severe and excessive worry has been recently linked to increased risk of conversion from mild cognitive impairment to Alzheimer's disease \[7\], and with increased risk of stroke and other cardiovascular events, after controlling for depression and vascular risk factors. Severe worry is also associated with interruption in functioning and reduced quality of life and with a higher risk of all-cause mortality in midlife and late-life. 2. Severe worry in late-life responds poorly to traditional interventions. Traditionally, severe worry has been confined to categories such as Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD), multiple lines of research support the presence of severe worry in other several other anxiety and mood disorders. Thus, while GAD is built around the concept of severe, uncontrollable worry, only 20% of severe older worriers qualify for a GAD diagnosis. This evidence supports a major recent shift in the conceptualization of worry as a transdiagnostic entity most suitable for dimensional investigations. Current late-life GAD treatment choices, including cognitive-behavioral therapy (CBT) and antidepressant pharmacotherapy, have proven moderately efficacious in reducing overall burden of anxiety but ineffective in reducing worry severity. The ineffectiveness of current treatments in reducing worry severity may be at the root of the chronic, relapsing course of late-life GAD, which is one of the least likely mental disorders to remit and most likely to relapse. 3. Novel circuit-based targets for intervention. Several neuroimaging studies have investigated both activation and functional connectivity among various brain regions involved in GAD - in adolescents and young adults. This research team has published exclusively on the neural markers of GAD in older adult participants. Also, very few studies used fMRI paradigms specifically tailored to induce worry or analyzed specifically the effect of worry severity at rest or during task. The investigators' current results point toward two different networks that may benefit from targeted interventions: the one associated exclusively with severe worry (amygdala-parahippocampus- rOFC- rSPG) and the one associated with maintenance/the protracted quality of worry (insula-caudate/thalamus-amygdala-parahippocampus). The investigators decided to target the network associated with worry severity due to both the richer literature regarding the pernicious effect of severe worry on both public health and treatment response but also due to accessibility for TMS of the rSPG. Overall, the worry severity network seems to implicate excessive limbic/paralimbic activation potentially amplified by the cognitive anticipation of the negative affective value of future events processed through the OFC as well as probable attempts to cognitively control the arousal and dysphoria through structures such as dACC and SPG. This speculation is in line with newer interpretations of pathologic worry that suggest severe worriers both maintain arousal in order to seek out potential solutions to the anxiogenic source while attempting to inhibit representations of the potential bad outcomes.

Interventions

DEVICETranscranial magnetic stimulation (TMS)

Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.

Sponsors

Carmen Andreescu
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants must have completed Dr. Andreescu's study R01MH108509/PRO15080120. * Penn State Worry Questionnaire score of 55 or above.

Exclusion criteria

* Any form of psychosis or Bipolar Disorder, dementia, a history of substance abuse within the last six months * Use of antidepressants within the last five to fourteen days (adequate washout interval to be determined by the principal investigator (PI) based on each specific antidepressant). For fluoxetine, the washout interval will be six weeks. However, for participants who are prescribed low dose psychotropics for pain, sleep disturbances, and/or medical conditions (e.g. amitriptyline for peripheral neuropathy, low dose trazodone as a sleep aid), these will be allowed in most circumstances. We will include participants on certain dosages of the most commonly prescribed antidepressants (for medical reasons) as follows: amitriptyline up to 50 mg/d, doxepin up to 50 mg/d, trazodone up to 100 mg/d, and imipramine up to 50 mg/d. We will review other cases individually and the PI will decide if the participants are eligible for the study and if they may continue the current medication. * Unable to complete MRI scans: presence of ferromagnetic metal in the body, claustrophobia * Contraindications for TMS: 1. Presence of a neurologic disorder or medical condition known to alter seizure threshold(e.g., stroke, aneurysm, brain surgery, structural brain lesion, brain injury, frequent/severe headaches) 2. Recurrent seizures or epilepsy in participant 3. Pregnancy 4. Metallic implants in body located at 30 cm or less from the position of the magnetic coil; presence in the body of other devices that may be affected by magnetic field (e.g. pacemakers). * Unable to temporarily discontinue benzodiazepines 48 hours prior to MRI scan. Participants on high doses of benzodiazepines (e.g., greater than or equivalent to 2 mg of lorazepam) will be excluded, given the complexity and potential complications of benzodiazepine taper/withdrawal.

Design outcomes

Primary

MeasureTime frameDescription
Change in Worry Severity From Baseline to Post-intervention as Measured by the Penn State Worry Questionnaire (PSWQ)Baseline and within 2 weeks post-TMS interventionPenn State Worry Questionnaire (PSWQ) scores range from 16 to 80 with higher levels indicating greater worry severity.
Participants Who Responded to TMSBaseline and the end of TMS intervention (approximately two weeks)The breakdown of participants who responded to TMS treatment; responders had Penn State Worry Questionnaire (PSWQ) scores that decreased by 30% or more from the baseline timepoint to the end of TMS treatment.

Countries

United States

Participant flow

Recruitment details

A total of 63 participants from the parent study, FINA, were phone screened for this study. 28 of those individuals signed consent for this study, but 4 of the 28 were deemed ineligible for the study prior to the TMS intervention, leaving a total of 24 participants being enrolled in the study that received at least 1 session of TMS treatment.

Pre-assignment details

After signing consent, but prior to starting the TMS intervention, participants were asked to complete a Penn State Worry Questionnaire to assess anxiety/worry levels. Individuals with a PSWQ score of 55 or higher qualified for the study intervention, and those with a score of 54 or lower were excluded from the study. Participants with low PSWQ scores were excluded as treatment was relevant only for high worriers.

Participants by arm

ArmCount
Transcranial Magnetic Stimulation (TMS)
Transcranial magnetic stimulation (TMS): Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
24
Total24

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyWithdrawal by Subject3

Baseline characteristics

CharacteristicTranscranial Magnetic Stimulation (TMS)
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
2 Participants
Age, Categorical
Between 18 and 65 years
22 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
23 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Penn State Worry Questionnaire (PSWQ) Score68.62 units on a scale
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
4 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
19 Participants
Region of Enrollment
United States
24 participants
Sex: Female, Male
Female
17 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 24
other
Total, other adverse events
23 / 24
serious
Total, serious adverse events
1 / 24

Outcome results

Primary

Change in Worry Severity From Baseline to Post-intervention as Measured by the Penn State Worry Questionnaire (PSWQ)

Penn State Worry Questionnaire (PSWQ) scores range from 16 to 80 with higher levels indicating greater worry severity.

Time frame: Baseline and within 2 weeks post-TMS intervention

Population: Participants who completed study TMS protocol

ArmMeasureGroupValue (MEAN)Dispersion
Transcranial Magnetic Stimulation (TMS)Change in Worry Severity From Baseline to Post-intervention as Measured by the Penn State Worry Questionnaire (PSWQ)PSWQ Score after TMS Treatment62.43 units on a scale (PSWQ)Standard Deviation 10.28
Transcranial Magnetic Stimulation (TMS)Change in Worry Severity From Baseline to Post-intervention as Measured by the Penn State Worry Questionnaire (PSWQ)Change from Baseline at Two Weeks6.19 units on a scale (PSWQ)Standard Deviation 8.5
Comparison: Mean difference using a paired t-testp-value: <0.005paired t-test
Primary

Participants Who Responded to TMS

The breakdown of participants who responded to TMS treatment; responders had Penn State Worry Questionnaire (PSWQ) scores that decreased by 30% or more from the baseline timepoint to the end of TMS treatment.

Time frame: Baseline and the end of TMS intervention (approximately two weeks)

Population: The breakdown of participants who responded to TMS treatment; responders had Penn State Worry Questionnaire (PSWQ) scores that decreased by 30% or more from the baseline timepoint to the end of TMS treatment.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Transcranial Magnetic Stimulation (TMS)Participants Who Responded to TMSTMS Responders2 Participants
Transcranial Magnetic Stimulation (TMS)Participants Who Responded to TMSTMS Non-responders19 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026